胸部巩固放疗在广泛期小细胞肺癌中的作用:随机对照试验的系统评价与Meta分析
该系统评价与Meta分析检索PubMed和Embase,纳入3项随机对照试验共690例广泛期小细胞肺癌患者,评估胸部巩固放疗的作用。汇总分析显示胸部巩固放疗显著改善无进展生存期(HR 0.72,95%CI 0.61-0.83),显著降低胸部进展作为首次进展部位的风险(RR 0.52,95%CI 0.44-0.61),但总生存期无显著获益(HR 0.88,95%CI 0.66-1.18)。
要点
- 胸部巩固放疗显著改善广泛期小细胞肺癌的无进展生存期(HR 0.72,95%CI 0.61-0.83)。
- 胸部巩固放疗显著降低胸部进展作为首次进展部位的风险(RR 0.52,95%CI 0.44-0.61)。
- 总生存期无显著获益(HR 0.88,95%CI 0.66-1.18)。
核心结论
- 3项随机对照试验的汇总Meta分析显示,胸部巩固放疗显著改善无进展生存期并减少胸部失败,但总生存期无显著获益。
- 需要进一步研究广泛期小细胞肺癌的亚分类(局限转移与广泛转移)、优化放疗整合策略(序贯与同步)及最佳放疗剂量,以识别可能获得显著总生存获益的亚组。
研究设计与样本
- 系统评价与Meta分析,检索PubMed和Embase,无语言、年份或发表状态限制,遵循PRISMA系统评价指南和Cochrane Meta分析方法。
- 检索识别1107条记录,去除重复后筛选922条记录,评估31篇全文,最终纳入3项随机对照试验,共690例患者。
- 提取效应估计值(风险比[HR]和置信区间[CI])及风险比,采用固定/随机效应模型估计治疗效果,并进行I²统计量和异质性统计。
主要发现
- 胸部巩固放疗显著改善无进展生存期(p<0.0001),HR 0.72(95%CI 0.61-0.83,I²=0%)。
- 胸部巩固放疗显著降低胸部进展作为首次进展部位的风险(p<0.001),相对风险0.52(95%CI 0.44-0.61,I²=0%)。
- 总生存期分析显示无显著获益(p=0.36),HR 0.88(95%CI 0.66-1.18,I²=52%)。
关键数值与推荐
- 无进展生存期:HR 0.72(95%CI 0.61-0.83,I²=0%),p<0.0001。
- 胸部进展作为首次进展部位:相对风险0.52(95%CI 0.44-0.61,I²=0%),p<0.001。
- 总生存期:HR 0.88(95%CI 0.66-1.18,I²=52%),p=0.36。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步研究广泛期小细胞肺癌的亚分类(局限转移与广泛转移)、优化放疗整合策略(序贯与同步)及最佳放疗剂量,以识别可能获得显著总生存获益的亚组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Extensive stage small cell lung cancer (ES-SCLC) carries a poor prognosis, and the thoracic progression is common. Consolidation radiation to thoracic disease (cRT) could improve progression-free survival (PFS) and overall survival (OS). We conducted an electronic search of PubMed and Embase with no language, year or publication status restrictions and evaluated randomised controlled trials (RCTs) addressing the role of cRT in ES-SCLC. Preferred Reporting of Systematic Reviews and Meta-Analyses guidelines for systematic review and Cochrane methodology for meta-analysis were followed. Effect estimates (hazard ratios [HRs] and confidence intervals [CIs]) and risk ratios were extracted, with a fixed/random-effects model created to estimate treatment effects. I2 statistics and heterogeneity statistics were performed. Comprehensive and systematic search identified 1107 records, after removal of duplicate records screened 922 records, assessed 31 full-text articles for eligibility and 3 RCTs with a total of 690 patients were included. Pooled analysis showed cRT significant improved PFS (p < 0.0001) with HR 0.72 (95% CI: 0.61-0.83, I2-0%). In addition, cRT significantly (p < 0.001) reduced the risk of thoracic progression as the first site of progression with a relative risk of 0.52 (95% CI: 0.44-0.61, I2-0%). OS analysis showed no significant (p = 0.36) benefit with HR of 0.88 (95% CI 0.66-1.18, I2-52%) with cRT. Pooled meta-analysis of 3 randomised controlled studies shows consolidation thoracic radiotherapy (RT) offers significant improvement in PFS and reduction in thoracic failures. Further research on subclassification of ES-SCLC (limited vs extensive metastasis), optimise strategy for RT integration (sequential vs concurrent) and optimal RT dose is needed to identify the subset of ES-SCLC likely to have significant OS benefit.
引用
- Rathod S, Jeremic B, Dubey A, et al. Role of thoracic consolidation radiation in extensive stage small cell lung cancer: A systematic review and meta-analysis of randomised controlled trials. Eur J Cancer. 2019. PMID: 30785014. doi:10.1016/j.ejca.2019.01.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。